XBiotech Stock (NASDAQ:XBIT)

Revenue Ownership Financials Chart

Previous Close

$2.87

52W Range

$2.50 - $8.32

50D Avg

$2.89

200D Avg

$4.22

Market Cap

$85.98M

Avg Vol (3M)

$94.71K

Beta

0.97

Div Yield

XBIT Company Profile

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Apr 15, 2015

Website

XBIT Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 22	Dec 21	Dec 20
Clinical Trial Service Revenue	-	$394.00K	$25.98M
Manufacturing Revenue	$4.01M	$18.00M	$18.00M
Product and Service, Other	-	-	$22.00K

Fiscal year ends in Dec 24 | Currency in USD

XBIT Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	$4.01M
Operating Income	$-42.47M	$-37.51M	$-34.49M
Net Income	$-38.53M	$-24.56M	$-32.90M
EBITDA	$-42.47M	$-35.77M	$-31.88M
Basic EPS	$-1.26	$-0.81	$-1.08
Diluted EPS	$-1.26	$-0.81	$-1.08

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 17May 07, 17 | 8:30 AM

Q4 16Mar 16, 17 | 8:30 AM

Q3 16Nov 15, 16 | 8:30 AM

Peer Comparison

Ticker	Company
KZR	Kezar Life Sciences, Inc.
YMAB	Y-mAbs Therapeutics, Inc.
SPRB	Spruce Biosciences, Inc.
KURA	Kura Oncology, Inc.
SNDX	Syndax Pharmaceuticals, Inc.
XNCR	Xencor, Inc.
CTMX	CytomX Therapeutics, Inc.
IVVD	Invivyd, Inc.
PTGX	Protagonist Therapeutics, Inc.